Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Marie-Claude
MC
Lefebvre
Elke
E
Hunsche
D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000191:economics*; D000077300:Bosentan; D002170:Canada; D003363:Cost Control; D016527:Drug Costs; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000191:economics*; D007555:Isoxazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D010666:Phenylpropionates / Q000008:administration & dosage / Q000191:economics; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D011687:Purines / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D011724:Pyridazines / Q000008:administration & dosage / Q000191:economics; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D013450:Sulfones / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000191:economics
D000959:Antihypertensive Agents; D007555:Isoxazoles; D010666:Phenylpropionates; D010879:Piperazines; D011687:Purines; D011724:Pyridazines; D013449:Sulfonamides; D013450:Sulfones; D013876:Thiophenes; D000068677:Sildenafil Citrate; C467894:ambrisentan; C106276:sitaxsentan; D000077300:Bosentan